Preliminary studies on the absorption, distribution and excretion of N-(2-hydroxyethyl)-maleopimarimidyl morpholide (3H-RU 18492) in the female rat and dog.
Following the oral administration of 3H-labelled N-(2-hydroxyethyl)-maleopimarimidyl morpholide (3H-RU 18 492) to rats and dogs, radioactivity was detected in plasma and the various tissues examined. However, the major fraction of the dose remained unabsorbed and the highest concentrations of radioactivity were found in the liver. In both species the major route of excretion of radioactivity was via the bile.
D000818:Animals; D001646:Bile / Q000378:metabolism; D004285:Dogs; D005260:Female; D006505:Hepatitis / Q000188:drug therapy; D007408:Intestinal Absorption; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D009025:Morpholines / Q000378:metabolism* / Q000627:therapeutic use; D051381:Rats; D014315:Triterpenes / Q000378:metabolism* / Q000627:therapeutic use
D009025:Morpholines; D014315:Triterpenes